Low-grade serous ovarian cancer: A unique disease

Current Oncology Reports

Volumn 10, Issue 6, 2008, Pages 519-523

  Schmeler, Kathleen M ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALTRETAMINE; B RAF KINASE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN;

ADJUVANT THERAPY; CANCER GRADING; CANCER RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOW GRADE SEROUS OVARIAN CANCER; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SURVIVAL TIME; TUMOR RECURRENCE;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; OVARY; RECURRENCE; TREATMENT OUTCOME;

EID: 58649099361     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0078-8     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58: 71-96.
2. Baak JP, Langley FA, Talerman A, Delemarre JF: Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986, 8: 354-357.
3. Stalsberg H, Abeler V, Blom GP, et al.: Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum Pathol 1988, 19: 1030-1035.
4. Bichel P, Jakobsen A: A new histologic grading index in ovarian carcinoma. Int J Gynecol Pathol 1989, 8: 147-155.
5. Shimizu Y, Kamoi S, Amada S, et al.: Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol 1998, 70: 2-12.
6. Silverberg SG: Histopathologic grading oA ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000, 19: 7-15.
7. Malpica A, Deavers MT, Lu K, et al.: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004, 28: 496-504.
8. Shimizu Y, Kamoi S, Amada S, et al.: Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998, 82: 893-901.
9. Staging classifications and clinical practice guidelines of gynecologic cancers by the FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70: 207-312.
10. Seidman JD, Horkayne-Szakaly I, Cosin JA, et al.: Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006, 103: 703-708.
11. Singer G, Shih IeM, Truskinovsky A, et al.: Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003, 22: 37-41.
12. Singer G, Oldt R III, Cohen Y, et al.: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95: 484-486.
13. Gilks CB: Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004, 23: 200-205.
14. Hsu CY, Bristow R, Cha MS, et al.: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004, 10: 6432-6436.
15. Singer G, Stohr R, Cope L, et al.: Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29: 218-224.
16. Shih IeM, Kurman RJ: Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res 2005, 11: 7273-7279.
17. Bonome T, Lee JY, Park DC, et al.: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005, 65: 10602-10612.
18. Jazaeri AA, Lu K, Schmandt R, et al.: Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003, 36: 53-59.
19. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al.: Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005, 24: 1053-1065.
20. Gershenson DM, Sun CC, Lu KH, et al.: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006, 108: 361-368.
21. Schmeler KM, Sun CC, Bodurka DC, et al.: Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008, 108: 510-514.
22. Gershenson DM, Sun CC, Bodurka DC, et al.: Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant [abstract]. Gynecologic Oncology 2008, 108: 7.
23. Shvartsman HS, Sun CC, Bodurka DC, et al.: Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as lowgrade serous carcinoma. Gynecol Oncol 2007, 105: 625-629.
24. Singer G, Kurman RJ, Chang HW, et al.: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160: 1223-1228.
25. O'Neill CJ, McBride HA, Connolly LE, et al.: High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007, 50: 773-779.
26. O'Neill CJ, Deavers MT, Malpica A, et al.: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005, 29: 1034-1041.
27. Wong KK, Lu KH, Malpica A, et al.: Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007, 26: 404-409.
28. Crispens MA, Bodurka D, Deavers M, et al.: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002, 99: 3-10.
29. Gilks CB, Bell DA, Scully RE: Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990, 9: 110-121.
30. Rettenmaier MA, Goldstein BH, Epstein HD, et al.: Serous psammocarcinoma of the ovary: An unusual finding. Gynecol Oncol 2005, 99: 510-511.
31. Giordano G, Gnetti L, Milione M, et al.: Serous psammocarcinoma of the ovary: A case report and review of literature. Gynecol Oncol 2005, 96: 259-262.
32. Akbulut M, Kelten C, Bir F, et al.: Primary peritoneal serous psammocarcinoma with recurrent disease and metastasis: A case report and review of the literature. Gynecol Oncol 2007, 105: 248-251.
33. Ansquer Y, Leblanc E, Clough K, et al.: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: A French multicenter study. Cancer 2001, 91: 2329-2334.
34. Mazzeo F, Berliere M, Kerger J, et al.: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003, 90: 163-169.
35. Santillan A, Kim YW, Zahurak ML, et al.: Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007, 17: 601-606.